Evidence map›Paper›PMID 40536723›Full record

ArticleAnnals of hematology2025

Efficacy and safety of rabbit ATLG and ATG in allogeneic hematopoietic stem cell transplantation for children with acquired severe aplastic anemia.

Senlin Zhang, Qi Ji, Li Gao, Qingwei Wang, Kai Cui, Minyuan Liu, Bohan Li, Yixin Hu, Yongping Zhang, Yuanyuan Tian and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Senlin Zhang *Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Qi Ji *Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Li Gao *Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Qingwei Wang *Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Kai Cui *Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Minyuan LiuDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Bohan LiDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Yixin HuDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Yongping ZhangDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Yuanyuan TianDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Shengqin ChengDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
Jun LuDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China. drlujun_sz@163.com.
Shaoyan HuDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China. hushaoyan@suda.edu.cn.

Funding

Soochow University of Medical School ML13101223Suzhou Projects 2023QN07Suzhou Projects DZXYJ202305, GSWS2023048, 2020ZKPB02The National Key Research and Development Program of China 2022YFC2502700the National Natural Science Foundation of China NSFC 82100229the National Natural Science Foundation of China NSFC 82170218, 82470221the National Natural Science Foundation of China NSFC 82200177the National Natural Science Foundation of China NSFC 82300244the National Natural Science Foundation of China NSFC 82400264the National Natural Science Foundation of China NSFC 82470127the Suzhou Municipal Key Laboratory SZS201615, SKY2022012, SZS2023014
6 · The paper itself

Abstract

Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome characterized by bone marrow hypoplasia and peripheral blood cytopenia. Without timely treatment, it frequently proves fatal. Rabbit anti-thymocyte globulin (ATG) and anti-human T lymphocyte globulin (ATLG) are widely used for graft-versus-host disease (GVHD) prophylaxis. However, their comparative efficacy in pediatric SAA remains undetermined. This study involved a single-center retrospective analysis of two ATG preparations in pediatric patients undergoing allo-HSCT. The primary endpoint was the incidence of GVHD and viral reactivation following HSCT. Secondary endpoints included overall survival (OS), GVHD-free and failure-free survival (GFFS), neutrophil engraftment, platelet engraftment, hemorrhagic cystitis (HC), tolerability, and toxicities within each group. A total of 124 pediatric SAA patients who underwent their first allo-HSCT between January 2019 and March 2024 were enrolled, with 35 receiving ATLG and 89 receiving ATG. OS, GFFS, GVHD, and HC incidence were comparable between the ATLG and ATG groups (OS: 95.2% vs. 92.9%, P = 0.617). ATLG significantly reduced the incidence of 180-day CMV (45.7% vs. 74.2%, P = 0.0062) and EBV reactivation (29.8% vs. 52.8%, P = 0.025). Additionally, ATLG was associated with fewer adverse events (AEs), including fever (P = 0.009) and rash (P = 0.018). ATLG demonstrated comparable efficacy to ATG in preventing GVHD and achieving OS in pediatric SAA patients undergoing allo-HSCT, while significantly reducing viral reactivation and AEs. These findings support ATLG as a safer alternative, warranting further prospective studies.

Indexed as

Anemia, AplasticAntilymphocyte SerumHematopoietic Stem Cell TransplantationAdolescentAnimalsChildChild, PreschoolFemaleGraft vs Host DiseaseHumansInfantMaleRabbitsRetrospective StudiesTransplantation, HomologousTreatment OutcomeAntilymphocyte SerumAllogeneic hematopoietic stem cell transplantationAnti-thymocyte globulinChildrenSevere aplastic anemia

Identifiers

PMID40536723
PMCPMC12283839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.